EN | UA
EN | UA

Help Support

Back

Filgotinib improves patient-reported outcomes in rheumatoid arthritis

Rheumatoid.Arthritis Rheumatoid.Arthritis
Rheumatoid.Arthritis Rheumatoid.Arthritis

What's new?

Filgotinib utilized as monotherapy or in combination is efficacious for the management of active rheumatoid arthritis.

According to a post hoc analysis of Phase 3 studies, the combination of once-daily filgotinib (FIL) 200 or 100 mg with methotrexate (MTX) or with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) offered sustained and prompt improvements in quality of life, disease activity, work productivity loss, fatigue, functional impairment, and presenteeism in rheumatoid arthritis people who were MTX-naïve or who had unsatisfactory response to MTX or biological DMARDs (bDMARDs).

Investigators undertook this study to explore filgotinib's effect on measures of patient-reported outcomes and health-related quality of life (HRQL) in people suffering from rheumatoid arthritis.

MTX-naïve subjects were given 200 or 100 mg filgotinib + MTX (FIL200+MTX, FIL100+MTX), 200 mg filgotinib monotherapy (FIL200) or MTX monotherapy through fifty-two weeks.

Those subjects having inadequate response to MTX (MTX-IR) were given FIL200+MTX, FIL100+MTX, 40 mg adalimumab +MTX (ADA+MTX), or placebo + MTX (rerandomized to FIL200+MTX or FIL100+MTX at week twenty-four) through fifty-two weeks. Subjects having inadequate response to bDMARD (bDMARD-IR) were given FIL200 or FIL100 or placebo with background stable csDMARDs for up to twenty-four weeks.

The patient-reported outcomes evaluated during the trials, included: (i) Patient Global Assessment of Disease Activity (PtGA), (ii) Medical Outcomes Study 36-Item Short Form Survey (SF-36), (iii) Health Assessment Questionnaire-Disability Index (HAQ-DI), (iv) Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA), (v) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), and (vi) physical/mental component summary (PCS/MCS).

Reporting of data was done in terms of least-squares mean alterations from the baseline. All the statistical comparisons were of filgotinib groups vs their control groups.

In MTX-naïve subjects, alteration from the baseline (standard deviation) in HAQ-DI was reported to be − 1.00 (0.03) with FIL200+MTX, − 0.94 (0.04) with FIL100+MTX, and − 0.91 (0.04) with FIL200 alone vs. − 0.81 (0.03) with MTX alone at week twenty-four. In MTX-IR subjects, alteration from the baseline in HAQ-DI was − 0.69 (0.04) with FIL200+MTX, − 0.57 (0.04) with FIL100+MTX, and − 0.60 (0.04) with ADA vs − 0.40 (0.04) with placebo+MTX at week twelve.

 

In bDMARD-IR subjects, alteration from the baseline in HAQ-DI was − 0.50 (0.06) with FIL200+csDMARD and − 0.46 (0.05) with FIL100+csDMARD vs − 0.19 (0.06) with placebo+csDMARD at week twelve. Alteration in PtGA, WPAI, SF-36 PCS and MCS, FACIT-Fatigue was noted to favor filgotinib therapy over ADA, MTX, and placebo. A higher percentage of participants reported substantial differences with filgotinib plus csDMARDs (including MTX) and with FIL200 monotherapy when compared to the comparators.

Hence, filgotinib (Janus kinase 1 inhibitor) improved the patient-reported outcomes across the patient populations. It appears to be an efficacious therapeutic choice for people having an unsatisfactory response to bDMARDs or MTX and for MTX-naïve people.

Source:

Arthritis Research & Therapy

Article:

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies

Authors:

Clifton O. Bingham III et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: